Glazer investigated an in vitro model of mixed cancer cell populations to determine the synergy between RF cadmium-selenide and indium-gallium-phosphide quantum dots or gold NPs, all conjugated with CD225 antibody, to target epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and cancer.